Search research articles
Contact Us
Filters
Showing results (31-40 of 42) with videos related to
Page
of 5
Sort By:
Current Atherosclerosis Reports
|
May 7, 2022
ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future
Arzu Kalayci, C Michael Gibson, Paul M Ridker, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology
|
November 8, 2008
Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome
John S Millar, Danielle Duffy, Ramprasad Gadi, et al.
American Journal of Cancer Therapy and Pharmacology
|
January 13, 2015
A pilot phase II Study of digoxin in patients with recurrent prostate cancer as evident by a rising PSA
Jianqing Lin, Tingting Zhan, Danielle Duffy, et al.
American Heart Journal
|
December 24, 2018
The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction
C Michael Gibson, Mathieu Kerneis, Megan K Yee, et al.
American Heart Journal
|
October 16, 2020
Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction
C Michael Gibson, John J P Kastelein, Adam T Phillips, et al.
Circulation. Cardiovascular Genetics
|
March 26, 2016
Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry
Emil M deGoma, Zahid S Ahmad, Emily C O'Brien, et al.
Journal of the American College of Cardiology
|
September 4, 2024
ApoA-I Infusions and Burden of Ischemic Events After Acute Myocardial Infarction: Insights From the AEGIS-II Trial
C Michael Gibson, Gerald Chi, Danielle Duffy, et al.
European Heart Journal
|
September 2, 2024
Apolipoprotein A-I infusions and cardiovascular outcomes in acute myocardial infarction according to baseline LDL-cholesterol levels: the AEGIS-II trial
C Michael Gibson, Danielle Duffy, Maria Cecilia Bahit, et al.
Journal of Clinical Lipidology
|
September 29, 2016
US physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registry
Zahid S Ahmad, Rolf L Andersen, Lars H Andersen, et al.
JACC. Advances
|
April 27, 2025
Impact of Apolipoprotein A-I Infusions on Cardiovascular Events Post-MI by Neutrophil-Lymphocyte Ratio and LDL-Cholesterol Levels
Sem A O F Rikken, C Michael Gibson, M Cecilia Bahit, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 42) with videos related to
Sort By:
Page
of 5
Current Atherosclerosis Reports
|
May 7, 2022
ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future
Arzu Kalayci, C Michael Gibson, Paul M Ridker, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology
|
November 8, 2008
Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome
John S Millar, Danielle Duffy, Ramprasad Gadi, et al.
American Journal of Cancer Therapy and Pharmacology
|
January 13, 2015
A pilot phase II Study of digoxin in patients with recurrent prostate cancer as evident by a rising PSA
Jianqing Lin, Tingting Zhan, Danielle Duffy, et al.
American Heart Journal
|
December 24, 2018
The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction
C Michael Gibson, Mathieu Kerneis, Megan K Yee, et al.
American Heart Journal
|
October 16, 2020
Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction
C Michael Gibson, John J P Kastelein, Adam T Phillips, et al.
Circulation. Cardiovascular Genetics
|
March 26, 2016
Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry
Emil M deGoma, Zahid S Ahmad, Emily C O'Brien, et al.
Journal of the American College of Cardiology
|
September 4, 2024
ApoA-I Infusions and Burden of Ischemic Events After Acute Myocardial Infarction: Insights From the AEGIS-II Trial
C Michael Gibson, Gerald Chi, Danielle Duffy, et al.
European Heart Journal
|
September 2, 2024
Apolipoprotein A-I infusions and cardiovascular outcomes in acute myocardial infarction according to baseline LDL-cholesterol levels: the AEGIS-II trial
C Michael Gibson, Danielle Duffy, Maria Cecilia Bahit, et al.
Journal of Clinical Lipidology
|
September 29, 2016
US physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registry
Zahid S Ahmad, Rolf L Andersen, Lars H Andersen, et al.
JACC. Advances
|
April 27, 2025
Impact of Apolipoprotein A-I Infusions on Cardiovascular Events Post-MI by Neutrophil-Lymphocyte Ratio and LDL-Cholesterol Levels
Sem A O F Rikken, C Michael Gibson, M Cecilia Bahit, et al.
Page
of 5